1Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
2Stanford Cancer Institute.
J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
美国国家综合癌症网络(NCCN)前列腺癌指南针对前列腺癌诊断后的分期和风险评估进行了阐述,其中包括局限性、区域性和转移性疾病的管理选择。该指南还包括疾病监测和复发性疾病治疗的建议。NCCN 前列腺癌专家组每年开会,根据新的临床数据以及 NCCN 成员机构和外部实体的意见,重新评估和更新他们的建议。本文总结了专家组在 2021 年更新指南时有关转移性去势抵抗性前列腺癌系统治疗的讨论。